Polycarboxylic Acid Or Salt Thereof Patents (Class 514/574)
  • Patent number: 10383893
    Abstract: Disclosed is a composition for reducing the levels or level of glucose, malondialdehyde-modified LDL, homocysteine, and/or C-reactive protein in the blood. Specifically disclosed is a composition for reducing the level of at least one substance selected from the group consisting of glucose, malondialdehyde-modified LDL, homocysteine, and C-reactive protein in the blood, which comprises the following components (a) and (b): (a) at least one component selected from the group consisting of vitamin B12, vitamin B6, and folic acid; and (b) at least one component selected from the group consisting of zinc, selenium, and an antioxidant vitamin.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: August 20, 2019
    Assignee: NUTRI CO., LTD.
    Inventor: Susumu Kawaguchi
  • Patent number: 10285961
    Abstract: In an embodiment of the present disclosure, there is provided a composition for dissolving calcium oxalate crystals thereby inhibiting/preventing further growth of crystals. In some embodiments, such a composition comprises at least one stereoisomer of hydroxycitrate, a derivative of the organic acid citrate. Such a method comprises administering to the subject an effective amount of the aforementioned composition. In another embodiment, the present disclosure pertains to a method of treating kidney stone disorder. Such a method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition. In yet another embodiment, the present disclosure relates to a method of treating calcium oxalate stone disease. In an embodiment, the method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: May 14, 2019
    Assignee: University of Houston System
    Inventors: Jeffrey D. Rimer, Jihae Chung, John Asplin
  • Patent number: 10155715
    Abstract: A fraction separated from crude crocetin by preparative HPLC, and identified using LC/MS and NMR as crocetinic acid, markedly regressed the proliferation and increased apoptosis in pancreatic cancer cells. Purified crocetinic acid showed more potency than 15 commercial or crude crocetin using proliferation and apoptosis as markers. Purified crocetinic acid also showed significant anti-tumorigenic activity against pancreatic cancer cells in a mouse model of pancreatic cancer. Given crocetinic acid's low toxicity, crocetinic acid could be used as a chemotherapeutic or chemopreventative agent for pancreatic cancer.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: December 18, 2018
    Assignees: The United States of America as represented by the Department of Veterans Affairs, University of Kansas, University of Missouri
    Inventors: Animesh Dhar, William G. Gutheil
  • Patent number: 10052318
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: August 21, 2018
    Assignee: YALE UNIVERSITY
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • Patent number: 10016356
    Abstract: The present invention relates to a novel sebum secretion inhibitor and use thereof for the production of cosmetic and pharmaceutical, notably dermatological, compositions, intended for preventing and/or reducing the secretion of sebum and notably of squalene.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: July 10, 2018
    Assignee: BASF Beauty Care Solutions France S.A.S.
    Inventors: Nabil Abdul-Malak, Corinne Reymermier
  • Patent number: 9988407
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: June 5, 2018
    Assignees: THE JOHNS HOPKINS UNIVERSITY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Patent number: 9961922
    Abstract: Improved animal feeds and/or waters are provided, which include amendments comprising one or more copolymer salts serving to reduce volatilized ammonia derived from the excrement of animals. The copolymers are preferably water soluble and have substantially equimolar amounts of maleic and itaconic moieties.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: May 8, 2018
    Assignee: Verdesian Life Sciences, LLC
    Inventor: John Larry Sanders
  • Patent number: 9889105
    Abstract: An in vivo method of inhibiting tumor growth, specifically pancreatic cancer, includes administering to a subject in need thereof an effective amount of a compound, composition, and/or a pharmaceutical formulation including crocetinic acid.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: February 13, 2018
    Assignees: U.S. Department of Veterans Affairs, Univ. of Kansas, The Curators of the Univ. of Missouri
    Inventors: Animesh Dhar, William G. Gutheil
  • Patent number: 9849104
    Abstract: Methods and formulations to reduce elevated levels of lipids and apolipoprotein B in subjects having type IIb hyperlipidemia. Methods for preventing, delaying or regressing complications of lipid disorders, including; type IIb hyperlipidemia, NAFLD, and NASH. Methods for preventing or delaying primary and secondary cardiovascular events. Kits useful for such methods. Methods for reducing hepatic fibrosis. Methods for reducing plasma fibrinogen levels.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: December 26, 2017
    Assignee: Gemphire Therapeutics Inc.
    Inventors: Charles L. Bisgaier, Daniela Carmen Oniciu
  • Patent number: 9820968
    Abstract: The present invention provides the compound Ormeloxifene [3, 4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy) phenyl-7-methoxy chroman] as useful in inducing differentiation in wide range of myeloid leukemias including acute promyelocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia where block in differentiation is common feature. Ormeloxifene induced differentiation that is marked by increase in differentiation marker proteins like C/EBP? and surface proteins such as cd11b and granulocyte colony stimulating factor receptor (GCSFr). Differentiated cells having neutrophil like morphology were observed when treated with 1.0 uM to 7.5 uM ORM which clearly indicates that ORM can induce differentiation in myeloid leukemia cells. At higher doses (5 uM to 7.5 uM) there is early onset of myeloid differentiation (24 to 48 h) with reduced no. of cells which is likely due to apoptotic effects of ORM at higher does.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: November 21, 2017
    Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
    Inventors: Pooja Pal, Savita Lochab, Jitendra Kumar Kanuajiya, Sabyasachi Sanyal, Arun Kumar Trivedi
  • Patent number: 9757407
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: September 12, 2017
    Assignee: The Trustees of Princeton University
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Patent number: 9468597
    Abstract: An aqueous topical serum having stabilized bioactive L-ascorbic acid has a pH of from 3.4 to 3.8 and comprises from 10% to 18% by weight of L(+)-ascorbic acid, 0.2% by weight retinyl propionate, and from 0.005% to 0.5% by weight of a mixture selected from the group consisting of glabridin, silibinin and thyme.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: October 18, 2016
    Assignee: Dr. Perry Skindustries, LLC
    Inventor: Arthur William Perry
  • Patent number: 9346914
    Abstract: The present invention is directed toward a series of polyesters synthesized utilizing propane diol with tunable ascetics and performance in cosmetic formulation. These novel propane diol polyesters are designed to have great esthetics in cosmetic formulation. The physical properties and aesthetics of the current invention can be tuned rapidly by controlling the fatty groups, as well as the molecular weight of the polymer. The resulting propane diol polyesters have outstanding aesthetics and physical properties.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: May 24, 2016
    Assignee: SURFATECH CORPORATION
    Inventor: Thomas George O'Lenick
  • Patent number: 9192188
    Abstract: A dietary supplement and method of supplementation comprises a vegetable component consisting essentially of juices extracted from two parts by weight fresh, unpeeled carrots; one part by weight fresh, unpeeled beet root; one part by weight of fresh, unpeeled cucumber; and a selected quantity of aloe vera juice. A cleansing component includes at least one of the following: about 2 fluid ounces (59.1 ml) of lemon juice; about 1.5-2 fluid ounces (44.3 to 59.1 ml) of lime juice; about 1 fluid ounce (29.6 ml) of aloe vera juice; and about 4-6 fluid ounces (118.3 to 177.4 ml) of cranberry juice. The vegetable component is ingested orally twice daily and the cleansing component is ingested orally once daily.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: November 24, 2015
    Inventor: Delphine Agatha O'Connor-Smith
  • Patent number: 9173838
    Abstract: The present invention relates to a method for the preparation of reverse micelles based on sterols, acylglycerols and metal salt and to reverse micelles obtained thereby. They are advantageously useful in the pharmaceutical and dietetic fields.
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: November 3, 2015
    Assignee: MEDESIS PHARMA SA
    Inventor: Jean-Claude Maurel
  • Publication number: 20150148287
    Abstract: A liquid excipient is added to a lock solution formulation containing a lower alcohol and an anti-coagulant, antibiotic, and/or anti-microbial, such as the ethanol and tri-sodium citrate lock solution formulation, to prevent citrate from crystallizing in catheters made from silicone. The locking solution could include a liquid excipient, such as glycerol, polysorbate-20, or polyethylene glycol (PEG)-400, along with a lower alcohol, such as ethanol, and an anti-coagulant, such as tri-sodium citrate, antibiotic, and/or anti-microbial.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Applicant: EXCELSIOR MEDICAL CORPORATION
    Inventors: Lecon Woo, William Anderson
  • Patent number: 9034390
    Abstract: The present invention generally relates to anti-microbial formulations and methods of their use and production. The formulations of the present invention are effective as broad spectrum anti-bacterial agents with efficacy against both Gram-negative and Gram-positive bacteria, as anti-viral agents with efficacy against both enveloped and non-enveloped viruses, and as anti-fungal agents with efficacy against both vegetative and spore forms of microorganisms and against biofilms. The present invention includes anti-microbial compositions that have at least one surfactant, at least one acid, at least one peroxide (preferably hydrogen peroxide), peracetic acid, and water. The anti-microbial Formulations of the present invention may additionally contain an organic salt. The organic salt may be a salt of the same acid that is used in the Formulation or a salt of a different acid. Methods for production and use of the inventive compositions are disclosed.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: May 19, 2015
    Assignee: BIONEUTRAL LABORATORIES CORPORATION
    Inventor: Andrew Kielbania, Jr.
  • Patent number: 9034319
    Abstract: A method of treating a cancer of the central nervous system in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of an agent which reduces blood glutamate levels and enhances brain to blood glutamate efflux to thereby treat the cancer of the central nervous system in the subject.
    Type: Grant
    Filed: May 26, 2008
    Date of Patent: May 19, 2015
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Vivian I. Teichberg, Angela Ruban-Matuzani
  • Publication number: 20150125426
    Abstract: A composition comprising medium chain dicarboxylic acids and/or derivatives of medium chain dicarboxylic acids can be used to treat or prevent metabolic disorders. The composition can particularly well be used to treat or prevent hyperglycemia, for example diabetes.
    Type: Application
    Filed: January 9, 2015
    Publication date: May 7, 2015
    Inventors: Geltrude Mingrone, Catherine Mace
  • Patent number: 9023892
    Abstract: A compound for use as an antimicrobial having a formula (A).
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: May 5, 2015
    Inventors: Allan James McKinley, Thomas V. Riley, Nigel Lengkeek, Scott Stewart, Ramiz Boulos
  • Publication number: 20150119321
    Abstract: A unique combination of weight loss modalities that produce 20-40 pounds of weigh loss in a six week treatment period. Treatment includes a meal plan chosen to provide adequate protein and nutrition during dieting and to assist metabolism of toxins created from the release of stored fat, high amounts of fiber to assist in collecting toxins and fat in the elimination system and to encourage peristaltic action in the bowel, a bowel toner to further increase peristaltic action in the bowel, stimulating liver functions of fat and toxins. The weight loss portion of the treatment is limited to six week segments, and added to the plurality of modalities comprising the invention, to further support the body during weight loss. By supporting the body during weight loss, his invention(s) avoids the “plateau” routinely experienced by existing weight loss systems, when the metabolism slows to avoid further damage from ultra-low calories, medications, bariatric surgeries, and other stressful programs.
    Type: Application
    Filed: April 5, 2013
    Publication date: April 30, 2015
    Inventor: Linda Duerler FINCH
  • Publication number: 20150110773
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Application
    Filed: May 23, 2013
    Publication date: April 23, 2015
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Patent number: 9012689
    Abstract: The present invention relates to a compound of formula A, wherein R is alkyl. Compound A may be used as an intermediate in the preparation of O-desmethyl venlafaxine or a salt thereof, and the present invention provides such a preparation, as well as a process for preparing the compound of formula A.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: April 21, 2015
    Assignee: Cipla Limited
    Inventors: Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao, Manohar Raghunath Surve
  • Publication number: 20150104429
    Abstract: Synthetic triterpenoids and methods of using the same to induce gene expression and differentiation of stem or progenitor cells are provided. Furthermore, the present invention provides methods for producing a cell, such as a stem or progenitor cell, with induced gene expression by contacting a stem or progenitor cell with an effective amount of a synthetic triterpenoid to induce the expression of one or more of SOX9 (Sex determining region Y-box 9), COL2A1 (Type II Collagen (alpha1)), TGF-?I, TGF-p2, TGF-33, BMP2, BMP4, BMPRII (Bone Morphogenic Protein Receptor II), SMAD (Small Mothers Against Decapentaplegic) 3, SMAD4, SMAD6, SMAD7, TIMP (Tissue Inhibitor of Metalloproteinase)-1 or TIMP-2 in the stem or progenitor cell, wherein the stem or progenitor cell is not a mesenchymal stem cell, periosteium cell or osteoprogenitor cell. In one embodiment, the stem or progenitor cell is multipotent.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 16, 2015
    Inventors: Gordon W. Gribble, Liangfeng Fu, Michael B. Sporn, Karen T. Liby
  • Publication number: 20150105460
    Abstract: Provided in the present invention are various labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases. Also provided in the present invention is a semen biotae extract comprising one or more labdane diterpenoid compounds and derivatives thereof for use in preparation of a pharmaceutical composition for preventing or treating neurodegenerative diseases.
    Type: Application
    Filed: June 4, 2012
    Publication date: April 16, 2015
    Inventors: Weiwei Su, Yonggang Wang, Fengyin Liang, Ning Wang, Zhong Pei, Haibin Liu
  • Publication number: 20150104531
    Abstract: Methods of inhibiting a phosphodiesterase (PDE) 7 enzyme such as PDE7A1 and methods for treating diseases associated with PDE7 using one or more trans-aconitic acid compounds, which can be isolated from plants.
    Type: Application
    Filed: October 13, 2014
    Publication date: April 16, 2015
    Inventors: Shui-Tein CHEN, I-Shu LEE, Yu-Chun CHEN
  • Patent number: 8999400
    Abstract: An aqueous disinfecting solution having a pH of from about 0.5 to about 6 consists essentially of hydrogen peroxide in a concentration of from about 0.05 to about 8 w/w % of the total solution, at least one anionic surfactant in a concentration of from about 0.02 to about 8 w/w % of the total solution, and at least one additional ingredient chosen from benzyl alcohol, an alcohol comprising one to six carbon atoms, and mixtures thereof, in a concentration of from about 0.1 to about 10 w/w % of the total solution.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: April 7, 2015
    Assignee: Virox Technologies Inc.
    Inventors: Jose A. Ramirez, Navid Omidbakhsh
  • Publication number: 20150093478
    Abstract: An absorbent pad that contains activated carbon to reduce confinement odor in a vacuum-packaged food product is provided. An embodiment of absorbent pad contains activated carbon and an antimicrobial agent that further reduces confinement odor by two mechanisms of action: reducing bacterial counts in the liquid purge that cause breakdown of carbohydrates and proteins in food products; and trapping of confinement odor-causing breakdown products by the activated carbon. The absorbent body in the absorbent pad actively draws in liquid purge and dissolved volatile breakdown products in the vacuum package that produce confinement odor, which produces greater and more rapid contact of odor-causing compounds with the activated carbon.
    Type: Application
    Filed: September 26, 2014
    Publication date: April 2, 2015
    Inventors: Sayandro Versteylen, Brett N. Stoll, Martin H. Michaels
  • Patent number: 8992954
    Abstract: The present invention relates to compositions comprising a derivative of 5-aminolevulinic acid (5-ALA), e.g. an ester of 5-ALA or a skin compatible salt thereof. Further, the invention relates to use of such compositions in methods of cosmetic treatment, particularly in methods of improving or otherwise enhancing the appearance of the skin.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: March 31, 2015
    Assignee: Photocure ASA
    Inventors: Oddveig Sellæg Helland, Stig Ove Johnsen, Enrique Alabata, Anja J. Jentoft, Aslak Godal
  • Publication number: 20150079144
    Abstract: A lubricious antiseptic coating material containing various solvents to achieve mutual miscibility and provide a generally homogenous product. A coating material is provided having an antipathogenic agent and a solvent for dissolving the same. The coating further includes a lubricious agent and a solvent for dissolving the same. Thus, the coating material contains antiseptic and lubricious properties suitable for application to a desired surface to kill or inhibit the growth of pathogens known to cause catheter related bloodstream infections.
    Type: Application
    Filed: November 19, 2014
    Publication date: March 19, 2015
    Inventors: Minh Quang Hoang, Mohammad A. Khan
  • Patent number: 8980344
    Abstract: The present invention provides a skin care product comprising at least two enhancers and at least one skin care ingredient, wherein the at least two enhancers are selected from cyclodextrin, pentasodium pentetate, phytic acid, potassium citrate, sodium citrate, potassium gluconate and sodium gluconate.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: March 17, 2015
    Inventor: Dennis F. Gross
  • Publication number: 20150064285
    Abstract: The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in providing Mg to a subject while avoiding adverse side effects such as diarrhea.
    Type: Application
    Filed: March 21, 2014
    Publication date: March 5, 2015
    Applicant: Magceutics, Inc.
    Inventors: Guosong LIU, Fei Mao
  • Patent number: 8962689
    Abstract: The present invention relates in general to medium chain dicarboxylic acids, their derivatives and their uses. In particular, the present invention relates to a composition comprising medium chain dicarboxylic acids and to the use of medium chain dicarboxylic acids and their derivatives for the preparation of products to treat or prevent metabolic disorders. The composition of the present invention can particularly well be used to treat or prevent hyperglycemia, for example diabetes.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: February 24, 2015
    Assignee: Nestec S.A.
    Inventors: Geltrude Mingrone, Catherine Mace
  • Patent number: 8957113
    Abstract: Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: February 17, 2015
    Assignee: Ferring B.V.
    Inventors: Keith A. Moore, Ralph A. Heasley, Jeffrey S. Greiwe, John W. Facemire, Jason D. Modest
  • Publication number: 20150034117
    Abstract: Compositions, kits, and methods for repairing bonds, for example, disulfide bonds, in hair or on the skin are disclosed. The compositions provide improved conditioning benefit for dry hair or moisturize the skin. The compositions also provide a long lasting moisturized feel and smooth feel to the skin or hair, without feeling greasy. The compositions contain one or more compounds that covalently bind at least two thiol groups in the hair or on the skin. Use of the binding compositions prevents reversion of the repaired bonds to their free thiol state, for at least one week or one month, or more, after a single application of the composition. Improved methods of styling hair, for example permanent hair waving, hair curling, hair coloring or highlighting, and hair straightening, are also provided.
    Type: Application
    Filed: August 13, 2014
    Publication date: February 5, 2015
    Inventors: Eric D. Pressly, Craig J. Hawker
  • Publication number: 20150031766
    Abstract: The present invention relates to compositions including surfactant peroxycarboxylic acid, methods for making these compositions, and methods for reducing the population of a microorganism.
    Type: Application
    Filed: October 14, 2014
    Publication date: January 29, 2015
    Inventors: Steven J. Lange, Junzhong Li
  • Patent number: 8937100
    Abstract: Cosmetic compositions comprising calcium citrate and at least one N-acylated aminoalcohol according to formula (I). Provided is a method of treating aged skin, comprising topically applying to the aged skin a composition comprising a compound of Formula (I) in an amount effective to provide an anti-ageing effect. The compound of Formula (I) is used to prevent skin and/or to help to maintain or improve moisture retention and/or to fight against the signs of skin ageing. The N-acylated aminoalcohol of formula (I) acts as a ceramidase inhibitor. The combination of at least one compound of formula (I) and calcium citrate stimulates keratinocyte differentiation.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: January 20, 2015
    Assignee: Cognis IP Management GmbH
    Inventors: Philippe Moussou, Olga Freis, Louis Danoux, Philippe Grisoni, Laurent Bailly
  • Patent number: 8933123
    Abstract: The present invention discloses polymorphic forms of O-desmethyl-venlafaxine succinate and processes for the preparation thereof.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: January 13, 2015
    Assignee: Cadila Healthcare Limited
    Inventors: Shriprakash Dhar Dwivedi, Ashok Prasad, Rushikesh Udaykumar Roy
  • Publication number: 20150005386
    Abstract: Methods of lowering the plasma LDL-C levels in a patient on a stable dose of statin where the patient has an LDL-C level above treatment goal. Methods of decreasing a patient's risk for developing coronary heart disease or having a recurrent cardiovascular event wherein the patient is on a stable dose of statin and the patient has an LDL-C level above treatment goal.
    Type: Application
    Filed: January 4, 2013
    Publication date: January 1, 2015
    Applicant: Michigan Life Therapeutics, LLC.
    Inventor: Charles L. Bisgaier
  • Patent number: 8912233
    Abstract: The present invention is directed toward a series of polyesters synthesized utilizing propane diol with tunable ascetics and performance in cosmetic formulation. These novel propane diol polyesters are designed to have great esthetics in cosmetic formulation. The physical properties and aesthetics of the current invention can be tuned rapidly by controlling the fatty groups, as well as the molecular weight of the polymer. The resulting propane diol polyesters have outstanding aesthetics and physical properties.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: December 16, 2014
    Assignee: SurfaTech Corporation
    Inventor: Thomas George O'Lenick
  • Patent number: 8911793
    Abstract: Systems and methods are described that facilitate generating and storing a concentrated copper and silver ion solution for treating a remote water volume (e.g., a pool, fountain, hot tub, cooling tower, etc.), in accordance with various features described herein. Citric acid and a water-soluble binding polymer are added to a volume of water. The intermediate solution is circulated past an ion generator for a predetermined time period, and copper ions generated thereby are bound by the binding polymer and/or chelated by the citric acid. Once a desired concentration of copper ions has been achieved, the concentrated solution is stored in portable vessels for transport to the remote water volume. Concentrated solution is added to the remote water volume to achieve a concentration therein of approximately 0.2-0.3 ppm.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: December 16, 2014
    Inventor: George Loucaides
  • Publication number: 20140364504
    Abstract: A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.
    Type: Application
    Filed: June 10, 2013
    Publication date: December 11, 2014
    Inventor: Naeem Uddin
  • Publication number: 20140357721
    Abstract: Provided is a redispersible powder-dispersed cosmetic which has a clear supernatant when unused, can exhibit good powder redispersibility when shaken upon use, has a good sensation, e.g., smoothness and non-stickiness, upon application to the skin, and has an excellent effect of dissolving/removing keratotic plugs. The cosmetic is characterized by comprising (A) succinic acid and/or a salt thereof, (B) bentonite and (C) a hydrophilic surfactant. Particularly preferably, the cosmetic additionally comprises a cellulose powder. It is preferred that the component (A), i.e., succinic acid and/or the salt thereof, is contained in an amount of 0.01 to 10.0 mass % relative to the total amount of the cosmetic.
    Type: Application
    Filed: December 25, 2012
    Publication date: December 4, 2014
    Applicant: SHISEIDO COMPANY, LTD.
    Inventors: Masayuki Shirao, Shigeru Mugikura
  • Patent number: 8901174
    Abstract: The subject application relates to methods of treatment of peripheral vascular disease (PVD) as well as ischemic osteonecrosis, peritoneal ischemia, chronic ocular disease, macular degeneration, or diabetic retinopathy, comprising administering a therapeutically effective amount of a trans carotenoid. The invention also relates to the use of such carotenoids as pretreatments for mammals at risk of an ischemic event.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: December 2, 2014
    Assignee: Diffusion Pharmaceuticals LLC
    Inventor: John L. Gainer
  • Publication number: 20140342000
    Abstract: A biocompatible porous scaffolds, especially bone regeneration scaffolds, comprising carbon-based nanoparticles, especially diamond nanoparticles, methods for the production of such biocompatible porous scaffolds, the use of such biocompatible porous scaffolds and methods for treating bone defects by inserting such biocompatible porous scaffolds comprising carbon-based nanoparticles into the bone defect.
    Type: Application
    Filed: December 12, 2012
    Publication date: November 20, 2014
    Inventors: Doris Steinmüller-Nethl, Heike Walles
  • Patent number: 8889195
    Abstract: Compositions containing calcium citrate malate wherein the calcium citrate malate exhibits one or more of: a pore area of at least about 30 m2/g; a dissolution rate of at least about 95% by weight of the calcium citrate malate in less than about 120 seconds.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: November 18, 2014
    Assignee: The Procter & Gamble Company
    Inventors: Ashok Premchand Luhadiya, Timothy William Dake, Glenn Richard Hudepohl, Donald Brown Compton
  • Publication number: 20140336260
    Abstract: A novel product for mold prevention and treatment is disclosed herein. The product comprises water, one or more anti-mold agents, one or more water-soluble fluoropolymers or other water-soluble polymers with similar properties, and one or more emulsifiers. In some embodiments, the product may further comprise one or more preservatives, one or more stabilizers, one or more binders, one or more fining agents, one or more firming agents, one or more thickeners, and/or one or more clarifying agents. The product may be non-toxic, biodegradable, effective for a long-period of time and against a wide variety of molds, and may also provide other features which render it safe for the environment as compared to other commonly used products in mold prevention and treatment.
    Type: Application
    Filed: July 24, 2014
    Publication date: November 13, 2014
    Inventors: Freddy Kai Klaffmo, Bert Jonny Nilsson, Britt Ann-Christine Langselius
  • Publication number: 20140311515
    Abstract: The invention relates to a liquid personal cleaning composition. The present inventors have found that inclusion selected di or tricarboxylic acid or a salt thereof, when combined with thymol or terpineol provide synergistic antimicrobial action in a rapid fashion and such efficacy is very low concentrations of thymol and/or terpineol.
    Type: Application
    Filed: October 15, 2012
    Publication date: October 23, 2014
    Applicant: Conopco, Inc, d/b/a UNILEVER
    Inventors: Sameer Keshav Barne, Amit Chakrabortty, Maya Treesa Saji
  • Patent number: 8864742
    Abstract: The present invention relates to locking compositions, kits containing the locking compositions and methods for maintaining the patency of vascular access devices or intravascular delivery devices employing the locking compositions. The locking compositions contain water, an anticoagulant and a viscosity agent and are free of heparin and alcohol.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: October 21, 2014
    Assignee: Cary Pharmaceuticals Inc.
    Inventor: Douglas D. Cary
  • Publication number: 20140308376
    Abstract: The present invention relates to compositions useful in treating hyperpigmentation and the various signs of dermatological aging in human skin. The present invention also relates to cosmetic compositions and methods of using such compositions that improve the aesthetic appearance of skin. Further, the present invention relates to methods of applying the compositions to the skin to effect treatment and to improve the aesthetic appearance of skin, particularly, by providing anti-aging benefits to the skin.
    Type: Application
    Filed: June 30, 2014
    Publication date: October 16, 2014
    Inventors: Harish Mahalingam, Christos D. Kyrou, Michael Traudt, Dmitri S. Ptchelintsev